Posters & Publications
Systemic administration of the di-apocarotenoid norbixin (BIO201) is neuroprotective, preserves photoreceptor function and inhibits A2E and lipofuscin accumulation in animal models of age-related macular degeneration and Stargardt disease. Published in AGING. 7 April 2020, Aging (Albany NY). 2020; . https://doi.org/10.18632/aging.103014
Biophytis Announces it Presented One Oral and One Poster Presentation at the MaculART meeting in Paris, France. Read the press release
Chronic oral treatment with BIO201 preserves retinal function in a dry AMD experimental model. Fontaine et al. Presented at the Association for Research in Vision and Ophthalmology (ARVO) 2018 Annual Meeting, April 29 – May 3, 2018, Honolulu, USA.
Involvement of peroxisome proliferator activator receptors (PPARs) in the photoprotective activity of the di-apo-carotenoid norbixin. Fontaine et al. Presented at the European Association for Vision and Eye Research (EVER) 20th Annual Meeting, September 27-30, 2017, Nice, France.
Abstract published in Acta Ophthalmologica. 95, S259, DOI: 10.1111/j.1755-3768.2017.0F070.
Evidence for the involvement of PPARs in the photoprotective activity of BIO201 (norbixin) on retinal pigment epithelium. Fontaine et al. Presented at the 17th Congress of the European Society of Retina Specialists (EURETINA), September 7-10, 2017, Barcelona, Spain.
Norbixin Protects Retinal Pigmented Epithelium Cells and Photoreceptors against A2E-Mediated Phototoxicity In Vitro and In Vivo. Fontaine et al. Published in PLOS ONE. 16 Dec 2016, 11(12): e0167793. doi: 10.1371/journal.pone.0167793.
BIO201: a new drug candidate for the treatment of dry AMD. Fontaine et al. Presented at the Association for Research in Vision and Ophthalmology (ARVO) 2016 Annual Meeting, May 1-5, 2016, Seattle, USA.